Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
Public ClinicalTrials.gov record NCT06705478. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Randomized Controlled Trial of Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes. An optional sub-study to evaluate treatment impact on the cerebrospinal fluid (CSF) profile will be conducted in a subset of 36 participants.
Study identification
- NCT ID
- NCT06705478
- Recruitment status
- Suspended
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 186 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 16, 2026
- Primary completion
- Dec 1, 2026
- Completion
- Dec 1, 2026
- Last update posted
- Jul 13, 2026
2026
United States locations
- U.S. sites
- 25
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama CRS | Birmingham | Alabama | 35222 | — |
| University of California, Los Angeles CARE Center CRS | Los Angeles | California | 90035 | — |
| UCSD Antiviral Research Center CRS | San Diego | California | 92103 | — |
| University of California, San Francisco HIV/AIDS CRS | San Francisco | California | 94110 | — |
| Harbor University of California, Los Angeles Center CRS | Torrance | California | 90502 | — |
| University of Colorado Hospital CRS | Aurora | Colorado | 80045 | — |
| Whitman-Walker Institute, Inc. CRS | Washington D.C. | District of Columbia | 20009 | — |
| The Ponce de Leon Center CRS | Atlanta | Georgia | 30308-2012 | — |
| Northwestern University CRS | Chicago | Illinois | 60611 | — |
| Massachusetts General Hospital CRS (MGH CRS) | Boston | Massachusetts | 02114 | — |
| Washington University Therapeutics (WT) CRS | St Louis | Missouri | 63110-1010 | — |
| New Jersey Medical School Clinical Research Center CRS (Site ID 31786) | Newark | New Jersey | 07103 | — |
| Weill Cornell Chelsea CRS | New York | New York | 10010 | — |
| Columbia Physicians & Surgeons (P&S) CRS | New York | New York | 10032 | — |
| Weill Cornell Uptown CRS | New York | New York | 10065 | — |
| University of Rochester Adult HIV Therapeutic Strategies Network CRS | Rochester | New York | 14642 | — |
| Chapel Hill CRS | Chapel Hill | North Carolina | 27599-7215 | — |
| Greensboro CRS | Greensboro | North Carolina | 27401-1020 | — |
| Cincinnati CRS | Cincinnati | Ohio | 45267-0405 | — |
| Case CRS | Cleveland | Ohio | 44106 | — |
| Ohio State University CRS | Columbus | Ohio | 43210 | — |
| Penn Therapeutics CRS | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh CRS | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt Therapeutics (VT) CRS | Nashville | Tennessee | 37204 | — |
| Houston Advancing Research Team CRS | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06705478, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 13, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06705478 live on ClinicalTrials.gov.